Some of these mechanisms are shown in Figure 2B. Evidence in support of BC influencing the patients’ immune responses in these conditions include findings that BC administration decreases serum tumour necrosis factor (TNF)-α levels, in addition to increasing the number of splenic NKT cells [156] and circulating CD4+ CD25+ HLA-DR Treg cells [155]. Here, CD4 is linked to breast cancer.